Another intriguing aspect of this study was that the authors opted to investigate the intermittent drug treatment with the chemotherapeutic agent dacarbazine, and they showed BRAFi-addicted melanoma cells were sensitized to this compound accompanied with MITF inhibition185. Here, MITF is linked to melanoma.